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Structured summary 
Aim: To evaluate congenital anomaly (CA)-medication exposure associations 
produced by the new EUROmediCAT signal detection system and determine which 
require further investigation. 
Methods:  Data from 15 EUROCAT registries (1995-2011) with medication 
exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical 
classification) and chemical subgroup (4th level) were analysed using a 50% false 
detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and 
SSRIs/psycholeptics already under investigation, 27 associations were evaluated.  If 
evidence for a signal persisted after data validation, a literature review was 
conducted for prior evidence of human teratogenicity. 
Results: 13/27 CA-medication exposure signals, based on 3-89 exposed cases, 
passed data validation. There was some prior evidence in the literature to support 6 
signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70-
8.53; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse 
transcriptase inhibitors (OR 5.01, 95% CI 1.99-14.20/OR 28.20, 95% CI 4.63-
122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 
1.70-22.93); hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10-1.76); 
hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28-2.70). 
Antipropulsives produced a signal for syndactyly while the literature revealed a signal 
for hypospadias. There was no prior evidence to support the remaining 6 signals 
involving the ordinary salt combinations, propulsives, bulk-forming laxatives, 
hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and 
selective serotonin agonists. 
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Conclusion: Signals which strengthened prior evidence should be prioritised for 
further investigation, and independent evidence sought to confirm the remaining 
signals. Some chance associations are expected and confounding by indication is 
possible. 
 
What is already known about this subject 
 There is insufficient information on the safety of the vast majority of 
medications when taken during pregnancy and more post-marketing 
surveillance of medication safety in pregnancy is needed  
 Signal detection based on spontaneous adverse effect reporting is biased and 
incomplete. 
What this study adds 
 The EUROmediCAT database, comprising data from population-based 
EUROCAT congenital anomaly registries, can be used for systematic signal 
detection and signal strengthening. 
 Our results strengthen 6 congenital anomaly-medication exposure signals in 
the literature 
 We generated 7 new signals which require independent confirmation as some 
may be chance findings. 
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Introduction 
Congenital anomalies (CAs), structural or functional abnormalities that are present 
from birth [1], are a major cause of infant mortality, childhood morbidity and long-
term disability [2].  They are a diverse group of disorders of prenatal origin and can 
be caused by a wide range of factors such as genetics, environmental agents, 
medications and physical conditions [3–5].  While a number of antenatal medication 
exposures are known to cause CAs [6], there is insufficient information on the risks 
and safety for the vast majority of medications [7].  The critical period for most major 
CAs is during organogenesis, in the first trimester of pregnancy [8].  It has been 
estimated that 22-54% of pregnancies [9,10] are exposed to prescription 
medications, excluding vitamins and minerals, during this time period.  As a result, 
the lack of information in relation to the safety of medication during human 
pregnancy is a serious public health problem [11].   
Typically, eligibility criteria for premarketing clinical trials exclude high risk individuals 
such as pregnant women [12].  The evaluation of medication safety in human 
pregnancy therefore relies on post-marketing surveillance to detect medication 
safety signals [13].  As defined by the World Health Organisation (WHO), a signal 
refers to ‘reported information on a possible causal relationship between an adverse 
event and a medication, the relationship being unknown or incompletely documented 
previously’ [14].   
Signals are detected when the observed number of reports is higher than expected 
for a particular medication-event combination [12,15].  Such statistical signals are 
frequently found because of the large number of comparisons made and do not 
necessarily mean that a causal association is present [12].  Even strong signals can 
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be generated by various forms of confounding [16] so once a signal is generated, 
signal strengthening and signal evaluation are necessary in order to reinforce or 
refute the potential signal [13,16,17].  While information on true medication safety 
signals should not be withheld from physicians and patients, false positive signals 
may cause substantial harm if they limit access to safe medications [17]. 
Traditionally signal detection has relied on national or international spontaneous 
reporting systems which pool reports of adverse medication events provided by 
healthcare providers, consumers and medication manufacturers [15].  Spontaneous 
report databases have a number of limitations such as under-, over- and duplicate 
reporting, limited information on concomitant medication or comorbidities and 
susceptibility to bias [12–14].  To overcome some of these limitations, programs 
have been initiated to make use of large data pools besides spontaneous reports 
such as healthcare databases and disease registries [13,18,19].  EUROmediCAT’s 
population based reproductive pharmacovigilance system is based on the European 
Surveillance of Congenital Anomalies (EUROCAT) network.  A statistical signal 
detection analysis was conducted using the EUROmediCAT central database to find 
highly statistically significant CA-medication exposure associations (see attached 
paper co-submitted to BJClinPharm). The aim of this paper is to describe the 
protocol used for evaluation of the signals produced by the EUROmediCAT 
statistical signal detection analysis, and to give the results of evaluation of 27 CA-
medication exposure associations to determine which should be prioritised for further 
investigation. We do not report here signals belonging to four medication groups 
which were separately investigated as part of the EUROmediCAT project: 
antiepileptic medications, insulin/insulin analogues, antiasthmatic medications and 
selective serotonin reuptake inhibitors and psycholeptics [20–23].   
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Methods 
Dataset and statistical signal detection analysis  
EUROCAT registries record all cases of major CA seen, among live births, fetal 
deaths ≥20 weeks’ gestation and termination of pregnancy for fetal anomaly 
(TOPFA) [24–26].  Births from 15 EUROmediCAT registries across 13 countries 
(1995-2011) were used to create a signal detection dataset, see supplementary table 
1 [Ref. attached paper].  This included 14,950 infants with a CA, excluding genetic 
conditions1 or isolated congenital dislocation of the hip, who were exposed to a 
medication in the first trimester, excluding folic acid, minerals, vitamins and/or topical 
medication [Ref attached paper co-submitted to BJClinPharm], coded to the 
Anatomic Therapeutic Chemical (ATC) classification system [27].  Data on maternal 
medication exposures are mostly obtained from prospectively recorded maternity 
records [28,29].   
The signal detection methodology used is previously described [see attached article]. 
In brief a case-malformed control approach was used where cases of a specific CA 
subgroup [30] were compared to all other CAs in terms of exposure to each specific 
medication.  The signal detection analysis was conducted using medications 
recorded at the 4th ATC level (chemical subgroup) and the 5th ATC level (chemical 
substance).  Use of different ATC codes for the same medication and changes to 
ATC codes over time were taken into account.  Medications with less than 3 exposed 
fetuses/babies were excluded from the analysis.  Any registry with no exposures to 
the medication of interest, or cases of the CA of interest, were also removed from 
each analysis.  Overall, 59 CA subgroups and 693 medication groups were tested, 
                                               
1 Chromosomal anomalies, genetic syndromes and skeletal dysplasias 
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resulting in 40,385 analyses.  In order to limit the number of false positive 
associations multiple testing procedures were implemented, using a 50% false 
discovery rate (FDR), where the cut-off p value for associations at the 5th ATC level 
was 0.00040 and at the 4th ATC level was 0.0011 [Ref. attached article].  As the 
individual medications at the 5th ATC level all contribute to the 4th ATC level group, if 
an association arose at both the 4th and 5th ATC level the 5th ATC level association 
was taken as the result.  This analysis produced 11 CA-medication exposure signals 
[Ref. attached article] which were from medication groups not already being 
investigated as part of the EUROmediCAT project [31] i.e. excluding antiepileptics, 
antidiabetics, antiasthmatics and SSRIs/psycholeptics. 
A previous analysis of the same dataset without some of the analytic refinements 
reported here (such as the amalgamation of duplicate ATC codes) [32], and cut-off p 
values for associations at the 5th and 4th ATC level of 0.00048 and 0.0028 
respectively, had identified an additional 16 signals. These original signals were 
included for further analysis as a comparison of the Odds Ratios (OR) and 95% CIs 
remained very similar between the original and revised analyses ( Figure 1 and 
Table 1), and although the FDR p-value threshold was slightly higher, it is not the 
sole criterion for identifying a potential association of interest. When both sets of 
results were combined there were 27 CA-medication exposure signals. Results are 
given combined and separately. 
Signal validation 
Initially, the exposed cases for each of the 27 CA-medication exposure associations 
were validated, in terms of diagnosis, medication exposure, and timing of exposure, 
with the local registries.   
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The OR based on these validated data were then adjusted for confounding by 
registry i.e. where a registry may differ in both their (recorded) exposure proportion 
and (recorded) CA subgroup proportion in such a way as to produce artificial 
relationships between the exposure and outcome. Adjustment for registry was done 
by conducting a meta-analysis in STATA/SE 12.1 using the fixed effect Mantel–
Haenszel method [33,34].  Continuity corrections were made as per the method by 
Sweeting et al. (2004) [35].   
With the exception of chromosomal anomalies, most CAs are not strongly associated 
with maternal age [36].  However, gastroschisis, an abdominal wall defect, is 
associated with young maternal age [37] and it was necessary to adjust the 
gastroschisis-medication exposure association for maternal age.  This was done by 
stratifying the meta-analysis by maternal age group [38], categorised as < 20, 20-24, 
25-29, 30-34, 35-39 and 40+.  
Those CA-medication exposure associations which persisted, when using validated 
data and adjusting for registry effects, were considered validated statistical signals.   
 
Signal description 
The validated statistical signals were then described in detail in terms of the signal 
ORs and 95% CIs, the adjusted ORs and 95% CIs using validated data, the number 
of exposed cases and the most prevalent concurrent medication exposures recorded 
among exposed cases.  In addition, the statistically significant CA-medication 
exposure associations which failed to meet the FDR threshold (FDR <50%) but 
which involved the same medication, or 3rd ATC level, exposure were also noted.   
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Signal literature review 
A literature review was then conducted, for the validated statistical signals, by 
searching REPROTOX, TOXBASE, the Developmental and Reproductive Toxicology 
Database (DART) and PubMed.  For those signals at the 5th ATC level this involved 
searching initially for the specific medication and then for the 4th ATC level 
medication group.  For signals at the 4th ATC level a literature review was conducted 
for both the medication group and each specific medication in the group.  
REPROTOX and TOXBASE were searched using the medication/group name alone.  
DART and PubMed were searched using the name of the medication/group 
combined with search terms for teratogen and CA, see Supplementary Document 1 
for more detail.  The reference lists of relevant articles were also searched.  Cohort 
and case-control studies were of particular interest but case reports/series were also 
noted where available as the evidence was limited for some medications.  The 
available published evidence was categorised according to the amount of evidence 
to support the signal in the human literature i.e. signal CA described in literature, 
teratogenicity leading to other CA described in the literature, or no evidence of 
teratogenicity in the literature.  When the evidence was based on case reports/series 
or a single case-control or cohort study the published evidence was noted as 
minimal. 
 
Ethical approval 
Ethical approval for this study was provided by the University of Ulster Nursing 
Research Governance Filter Committee.   
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Results 
Signal validation 
Out of the 27 original CA-medication exposure associations 14 (7 from the original 
and 7 from the revised analysis) were not validated as independent signals: one was 
a duplicate signal as more than one formulation of the medication is available (the 
combined contraceptive levonorgestrel and ethinylestradiol); for 5 CA-medication 
exposure associations a proportion of the CA cases and/or first trimester medication 
exposures could not be verified so that the OR using validated data more than 
halved to less than 1.5; 8 CA-medication exposure associations were explained by 
confounding by registry. 
This left 13 (9 from the original and 4 from the revised analysis) validated unique CA-
medication exposure signals related to gastrointestinal medications (n=4), 
antihypertensives (n=1), female sex hormones (n=3), medications used in infertility 
treatments (n=2), antiretrovirals (n=2) and selective serotonin (5HT1) agonists (n=1). 
 
Signal description  
The 13 statistical signals were based on between 3 and 89 confirmed CA cases with 
first trimester medication exposures (Table 1). 
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Table 1 Description of validated signals 
ATC code/s Medication/s 
and Congenital Anomaly 
Signal OR (95% CI)  p value 
Number of 
cases 
(confirmed 
1st trimester 
exposures) 
Mantel-
Haenszel 
adjusted* 
OR using 
validated 
data (95% 
CI) 
Most prevalent 
concurrent medication 
exposures among cases 
(n) 
Significant positive 
medication-CA exposure 
associations not meeting 
FDR criteria (unvalidated§) 
A02AD01 Ordinary salt 
combinations and cleft lip 
with or without cleft palate 
2.38 (1.46-3.72) 0.00036 23 (21) 
1.70 (1.06-
2.72) 
None (4), piperazine 
derivatives R06AE(2), 
other medications for 
peptic ulcer and gastro-
oesophageal disease 
A02BX (2), paracetamol 
N02BE01 (2), cisapride 
A03AF02 (1) 
A02AD01 and cleft palate (OR 
2.65, 95% CI 1.49-4.42) 
A02AD01 and 
Anopthalmos/micropthalmos 
(OR 5.17, 95% CI 1.57-13.35) 
A02AB04 and polydactyly (OR 
16.62, 95% CI 2.20-124.82) 
A03FA Propulsives 
(metoclopramide, cisapride, 
domperidone, bromopride, 
alizapride, clebopride and 
itopride) and total 
anomalous pulmonary 
venous return‡ 
6.41 (1.89-17.46) 0.0021 5 (5) 
10.49 
(3.45-
31.93) 
None (10), levothyroxine 
sodium H03AA01 (2), 
omeprazole A02BC01 (1), 
prochlorperazine N05AB04 
(1), promethazine 
R06AD02 (1) 
None 
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A06AC Bulk-forming 
laxatives (ispaghula (psylla 
seeds), ethulose, sterculia, 
linseed, methylcellulose, 
triticum (wheat fibre), 
polycarbophil calcium, 
ispaghula combinations, 
sterculia combinations and 
linseed combinations) and 
anencephalus and similar‡ 
8.98 (2.29-25.53)  0.0015 4 (4) 
6.38 (2.23-
18.24) 
None (2), amoxicillin 
J01CA04 (1), follitropin alfa 
G03GA05 (1), chorionic 
gonadotrophin G03GA01 
(1), levonorgestrel and 
ethinylestradiol G03AA07 
(1) 
A06AC  and ventricular septal 
defect (OR 2.69, 95% CI 1.34-
5.21) 
A06AC and cleft lip with or 
without cleft palate (OR 3.37, 
95% CI 1.16-8.10) 
A06AC  and neural tube 
defects (OR 3.64, 95% CI 
1.11-9.32) 
A06AD and club foot/talipes 
equinovarus (OR 2.21, 95% 
CI 1.09-4.09) 
A07DA Antipropulsives 
(diphenoxylate, opium, 
loperamide, difenoxin, 
loperamide oxide, morphine 
combinations and 
loperamide combinations) 
and syndactyly‡ 
10.12 (2.42-32.05) 0.0013 4 (4) 
6.41 (2.28-
18.00) 
None (3), nitrofurantoin 
J01XE01 (1) 
None 
C02DB 
Hydrazinophthalazine 
derivatives (dihydralazine, 
hydralazine, endralazine, 
5.78 (1.39-22.81)  0.0077 5 (5) 
2.78 (1.07-
7.24) 
None (3), methyldopa 
C02AB01 (2), diprophylline 
R03DA01 (1) 
None 
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cadralazine) and Atrial 
septal defect (ASD)‡ 
G03AB03 or G03AA07 
Levonorgestrel and 
ethinylestradiol and 
gastroschisis‡ 
4.10 (1.70-8.53) 0.0013 8 (8) 
2.95 (1.38-
6.33)¥ 
None (6), trimethoprim 
J01EA01 (1), ibuprofen 
M01AE01 (1) 
G03AB03 or G03AA07 and 
bladder exstrophy and/or 
epispadia (OR 7.05, 95% CI 
1.36-23.2) 
G03AA09 and neural tube 
defects (OR 4.88, 95% CI 
1.23-14.18) 
G03AA13 and CHD (OR 6.12, 
95% CI 1.16-60.46) 
G03AA and congenital 
cataract (OR 3.47, 95% CI 
1.09-8.54) 
G03AA and anencephalus 
and similar (OR 2.69, 95% CI 
1.05-5.76) 
G03DA Pregnen (4) 
derivatives (gestonorone, 
medroxyprogesterone, 
hydroxyprogesterone and 
6.60 (1.70-22.93) 0.0035 5 (5) 
7.60 (2.34-
24.67) 
None (3), estradiol 
combinations G03CA53 
(1), estradiol G03CA03 (1) 
G03DA04 and ASD (OR 1.38, 
95% CI 1.12-1.68) 
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progesterone) and complete 
absence of a limb‡ 
G03DC and ASD (OR 1.79, 
95% CI 1.09-2.82) 
G03DC and neural tube 
defects (OR 2.21, 95% CI 
1.07-4.13) 
G03DC and limb reduction 
(OR 2.26, 95% CI 1.00-4.47) 
G03DB Pregnadien 
derivatives (dydrogesterone, 
megestrol, medrogestone, 
nomegestrol, demegestone, 
chlormadinone, 
promegestone and 
dienogest) and 
hypospadias‡ 
1.40 (1.10-1.76) 
0.0036 
91 (89) 
1.51 (1.15-
1.98) 
None (59), drotravine 
A03AD02 (7), 
hydroxyprogesterone 
G03DA03 (6), aspirin 
B01AC06 (4), 
progesterone G03DA04 
(3), A03AD02 (5)  
G03DB and congenital heart 
defects (CHD) (OR 1.39, 95% 
CI 1.19-1.61) 
G03GB Synthetic ovulation 
stimulants (cyclofemil, 
clomifene and epimestrol) 
and hypospadias 
1.89 (1.28-2.70) 0.00073 37 (36) 
1.92 (1.35-
2.74) 
None (22), progesterone 
G03DA04 (4), chorionic 
gonadotropin G03GA01 
(4), levothyroxine sodium 
H03AA01 (3), labetalol 
C07AG01 (2) 
G03GA and laterality (OR 
4.92, 95% CI 1.72-11.47) 
G03GA08 and ASD (OR 1.95, 
95% CI 1.21-3.02) 
G03GA01 and congenital 
constriction bands/amniotic 
band (8.00, 95% CI 1.53-
26.59) 
G03GA02 and neural tube 
defects (OR 3.12, 95% CI 
1.19-6.98) 
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G03GA04 and ventricular 
septal defect (OR 7.34, 95% 
CI 1.24-50.14) 
G03GA01 and bladder 
exstrophy and/or epispadia 
(OR 6.45, 95% CI 1.25-20.97) 
L02AE Gonadotropin 
releasing hormone 
analogues (buserelin, 
leuprorelin, goserelin, 
triptorelin and histrelin) and 
laterality anomalies‡$ 
13.34 (2.52-45.08) 0.0021 3 (3) 
9.09 (2.75-
30.08) 
follitropin alfa G03GA05 
(2), chorionic 
gonadotrophin G03GA01 
(2), urofollitropin G03GA04 
(1), progesterone 
G03DA04 (1) 
L02AE04 and severe CHD 
(OR 4.52, 95% CI 1.01-16.3) 
J05AF Nucleoside and 
nucleotide reverse 
transcriptase inhibitors 
(zidovudine, didanosine, 
zalcitabine, stavudine, 
lamivudine, abacavir, 
tenofovir disoproxil, adefovir 
dipivoxil, emtricitabine, 
entecavir, telbivudine, 
clevudine) and congenital 
heart defects (CHD) 
5.01 (1.99-14.2) 0.00012 18 (20) # 
2.04 (1.17-
3.55) # 
None (8), protease 
inhibitors J05AE (8), 
ritonavir J05AE03 (4), 
lopinavir and ritonavir 
J05AE06 (3), 
sulfamethoxazole and 
trimethoprim J01EE01 (1), 
combinations of 
sulfonamides and 
trimethoprim, including 
derivatives J01EE (1) 
J05AF and severe CHD (OR 
3.53, 95% CI 1.15-9.22) 
J05AB11 and polydactyly (OR 
7.69, 95% CI 1.38-28.46) 
J05AE03 and CHD (OR 5.92, 
95% CI 1.05-60.21) 
18 
 
J05AF30 Combinations of 
nucleoside and nucleotide 
reverse transcriptase 
inhibitors and pulmonary 
valve stenosis 
28.2 (4.63-122.24) 
0.00039 
3 (4) # 
5.08 (1.83-
14.07) # 
Nucleoside and nucleotide 
reverse transcriptase 
inhibitors J05AF (3), 
protease inhibitors J05AE 
(2), nevirapine J05AG01 
(1), non-nucleoside 
reverse transcriptase 
inhibitors J05AG (1), 
lopinavir and ritonavir 
J05AE06 (1), saquinavir 
J05AE01 (1) 
 
J05AF30 and ASD (OR 6.08, 
95% CI 1.03-25.55) 
N02CC Selective serotonin 
(5HT1) agonists 
(sumatriptan, naratriptan, 
rizatriptan, almotriptan, 
eletriptan and frovatriptan) 
and congenital constriction 
bands/amniotic band‡ 
12.97 (2.46-43.53) 0.0022 3 (3) 
15.58 
(4.44-
54.62) 
ispaghula A06AC01 (1), 
‘other’ anti-obesity 
medications A08AX (1), 
dalteparin B01AB04 (1), 
fluconazole J02AC01 (1), 
ibuprofen M01AE01 (1) 
N02CC and encephalocele 
(OR 6.12, 95% CI 1.20-19.38) 
N02CC and pulmonary valve 
atresia (OR 5.25, 95% CI 
1.04-16.48) 
N02CC05 and ASD (OR 
11.99, 95% CI 1.6-89.73) 
N02CC06 and club 
foot/talipes equinovarus (OR 
8.59, 95% CI 1.33-44.29) 
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More detail is provided than usual for p values due to the number of decimal places 
of relevance to the interpretation of the signal detection results. 
‡Signal from original analysis not meeting revised FDR p-value threshold. 
*Using validated data and adjusting for registry. 
§Not validated in terms of CA or medication exposure and not adjusted for registry. 
¥Adjusted for maternal age category.  
$Laterality group includes atrial isomerism, dextrocardia, situs inversus, broncho-pulmonary 
isomerism, asplenia and polysplenia.  
#Includes J05AX04, J05AB05, J05AB07, J05AB08, J05AB10, J05AF, J05AF01-12, 
J05AF30, J05AR01-09 and J05AR11-13 in adjusted analysis due to changes over time in 
the ATC coding of Ns/NtRTIs (including in combination).   
 
Signal literature review 
Of the 13 validated signals for which a literature review was conducted, previous 
evidence in the literature was found for 6 (Table 2).
20 
 
Table 2 Results of literature review relating to 13 validated signals 
Signal Evidence 
to support 
signal 
Medication uses and literature relating to their 
teratogenicity in humans 
A02AD01 
Ordinary salt combinations 
Cleft lip with or without cleft palate 
 
C£ 
Ordinary salts are combinations and complexes of 
aluminium, calcium and magnesium compounds used as 
antacids.  There is no evidence relating specifically to the 
teratogenicity of the ordinary salt combinations. One case-
control study explores the teratogenicity of combinations and 
complexes of aluminium, calcium and magnesium.  No 
increase in all CAs combined among those treated with 
aluminium magnesium hydrocarbonate (OR 1.5, 95% CI 0.3-
8.9) or aluminium magnesium hydroxide (OR 0.6, 95% CI 
0.2-2.4) was reported [39].   
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A03FA  
Propulsives (metoclopramide, cisapride, 
domperidone, bromopride, alizapride, clebopride 
and itopride) 
Total anomalous pulmonary venous return 
C 
Propulsives enhance gastrointestinal motility and are used to 
treat nausea and vomiting.  Cohort studies have found no 
increase in the risk of all CAs combined [40–44], 
hypospadias or orofacial clefts [45] following exposure to the 
propulsives.  There was no evidence of an association 
between transposition of the great vessels, ventricular septal 
defect (VSD), atrial septal defect (ASD), Tetralogy of Fallot, 
pulmonary valve stenosis or coarctation of the aorta  [46] 
and first trimester exposure to metoclopramide (A03FA01).  
A retrospective cohort study found no significant association 
between first trimester exposure to metoclopramide and 
‘other anomalies of the circulatory system’, a group which 
includes total anomalous pulmonary venous return [47].  
However, the number of cases involved in this group was 
small and it is unclear what proportion, if any, had total 
anomalous pulmonary venous return.  No studies have 
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looked specifically at the risk of total anomalous pulmonary 
venous return. 
A06AC  
Bulk-forming laxatives (ispaghula (psylla seeds), 
ethulose, sterculia, linseed, methylcellulose, 
triticum (wheat fibre), polycarbophil calcium, 
ispaghula combinations, sterculia combinations 
and linseed combinations)  
Anencephalus and similar anomalies  
C£ 
Bulk-forming laxatives are used to treat constipation.  The 
single cohort study exploring the teratogenciity of ispaghula 
(A06AC01) found no significant difference in the rate of all 
CAs combined between those who were exposed in the first 
trimester and those who were not [48].  
A07DA 
Antipropulsives (diphenoxylate, opium, loperamide, 
difenoxin, loperamide oxide, morphine 
combinations and loperamide combinations) 
B 
Antipropulsives are used to treat diarrhoea.  Two cohort 
studies explore the teratogenicity of loperamide (A07DA03) 
and found no increase in all CAs combined [49].  An 
association was found between loperamide exposure and 
hypospadias (RR 3.2, 95% CI 1.3– 6.6, n=7) but multiple 
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Syndactyly comparisons mean that this may have been due to chance 
[50]. 
C02DB  
Hydrazinophthalazine derivatives (dihydralazine, 
hydralazine, endralazine, cadralazine) 
Atrial septal defect (ASD) 
C£ 
Hydrazinophthalazine derivatives act on arteriolar smooth 
muscle and are used to treat hypertension.  A single case-
control study found no significant association between 
dihydralazine (C02DB01) exposure, before and throughout 
pregnancy, and all CAs combined [51]. 
G03AB03/G03AA07 
Levonorgestrel and ethinylestradiol  
Gastroschisis  
A 
Levonorgestrel and ethinylestradiol is a combined oral 
contraceptive containing both an oestrogen and a 
progestogen.  Evidence specifically relating to levonorgestrel 
and ethinylestradiol is limited to one large case-control study 
where 6/133 (4.5%) CA case and 8/129 (6.2%) non-
malformed control infants were exposed to levonorgestrel 
and ethinylestradiol [52].  Exposure to oral contraceptives in 
early pregnancy does not increase the risk of all CAs 
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combined [53,54], neural tube defects (NTD) [55–57], CHD 
[54] or orofacial cleft [58].  The evidence relating to 
gastroschisis is conflicting with some articles showing a 
significant association (68% of gastroschisis cases exposed 
vs. 26% of malformed controls [59]; aOR 1.8, 95% CI 1.3-
2.7, n=40 [60] ) and others showing none [61,62].  The same 
is true for genital anomalies [63–68].  One case-control study 
describes an increased risk of urinary tract anomalies 
following first trimester exposure to oral contraceptives [69].   
G03DA  
Pregnen (4) derivatives (gestonorone, 
medroxyprogesterone, hydroxyprogesterone and 
progesterone) 
Complete absence of a limb 
A 
Pregnen (4) derivatives are progestogens, compounds with 
biological activity similar to progesterone, used in hormone 
replacement therapy, infertility and to treat menstrual 
problems.  Cohort and case-control studies found no 
significant increase in all CAs combined with any of the 
pregnen (4) derivatives [70–76].  A cohort study found that 
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medroxyprogesterone (G03DA02) increases the rate of 
CHDs, gastro-intestinal defects, CAs of the integument, 
chromosome defects and all other defects. These findings 
may be due to chance as multiple comparisons were made 
and the range of defects including chromosomal defects is 
not plausible [77].  A number of case-control studies have 
found a significant association between hypospadias and 
both hydroxyprogesterone (G03DA03) and progesterone 
(G03DA04) [78–80].  However, other studies have found no 
association [66,81,82] and recall bias is a concern [83].  In 
the 1960s and 70s a number of studies were published 
linking ‘sex hormones’ with an increased incidence of non-
genital congenital malformations such as CHDs and limb 
reduction defects [84–90].  However, the evidence 
supporting the link between progestogens and contraceptive 
agents with non-genital malformations was contradictory, 
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poor methodologically and the study material lacked 
uniformity [73,91,92].  By 1993 the controversy surrounding 
this issue meant that there had been 20 review articles 
written on this subject, none of which concluded that sex 
hormones produced non-genital organ teratogenesis [93,94]. 
G03DB  
Pregnadien derivatives (dydrogesterone, 
megestrol, medrogestone, nomegestrol, 
demegestone, chlormadinone, promegestone and 
dienogest) 
Hypospadias  
A 
Pregnadien derivatives are also progestogens and are used 
as per the pregnadien derivatives.  A review of case-reports 
and 3 very small trials found no increase in all CAs combined 
with dydrogesterone (G03DB01) [95–98].  The broader 
medication group, the progestogens, have been associated 
with hypospadias [68,81,99] but these findings have not 
been consistent [66,79,83,100]. 
G03GB  
A 
Synthetic ovulation stimulants are used in infertility 
treatment.  Across cohort and case-control studies there is 
no evidence that exposure to clomiphene citrate (G03GB02) 
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Synthetic ovulation stimulants (cyclofemil, 
clomifene and epimestrol) 
Hypospadias  
in the periconceptional period increases the rate of all CAs 
combined.  There is  conflicting evidence of an association 
with NTDs [101–103].  Clomiphene has been associated with 
coarctation of the aorta [104,105], anencephaly, Dandy 
Walker malformation, septal heart defects, muscular 
ventricular septal defects, esophageal atresia, cloacal 
exstrophy, craniosynostosis and omphalocele but multiple 
comparisons and small numbers of cases make these 
findings tentative [105].  An association between 
periconceptional clomiphene exposure and the more severe, 
proximal forms of hypospadias [66,106–108], but not all 
forms of hypospadias combined [109,110], has been 
described. 
L02AE  
C£ 
Gonadotropin releasing hormone analogues are used in 
infertility treatment.  Evidence relating to the teratogenicity of 
the GnRHa’s is limited to case reports/series [111–114].  
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Gonadotropin releasing hormone analogues 
(GnRHa) (buserelin, leuprorelin, goserelin, 
triptorelin and histrelin) 
Laterality  
There is no evidence for a pattern of anomalies but the 
numbers reported are small and there is potential for 
reporting bias. 
J05AF  
Nucleoside and nucleotide reverse transcriptase 
inhibitors (Ns/NtRTIs) (zidovudine, didanosine, 
zalcitabine, stavudine, lamivudine, abacavir, 
tenofovir disoproxil, adefovir dipivoxil, emtricitabine, 
entecavir, telbivudine, clevudine) 
Congenital heart defects (CHD)  
A 
The Ns/NtRTIs are used to treat HIV/AIDS and chronic 
hepatitis.  Case-control, cohort studies and a manufacturer 
maintained pregnancy registry explore the teratogenicity of 
individual Ns/NtRTIs and the group as a whole.  There is no 
evidence that first trimester exposure to any of the individual 
Ns/NtRTIs, or the group as a whole, increases the rate of all 
CAs combined [115–119]  First trimester exposure to 
zidovudine (J05AF01) has been found to increase the risk of 
CHD [119,120], but this has not been a consistent finding 
[121,122].  A significant association between first trimester 
exposure to ARV regimes containing at least one Ns/NtRTI 
J05AF30  
A 
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Combinations of nucleoside and nucleotide reverse 
transcriptase inhibitors  
Pulmonary valve stenosis (PVS)  
and CHD is reported [123].  There is no evidence relating to 
the risk of PVS as a specific CHD.  Small numbers of cases 
have also suggested an increased risk of Central Nervous 
System (CNS) anomalies [122] and hypospadias [124] 
following first trimester exposure to zidovudine and head and 
neck defects following first trimester exposure to didanosine 
(J05AF02) [119].  
N02CC  
Selective serotonin agonists (sumatriptan, 
naratriptan, rizatriptan, almotriptan, eletriptan and 
frovatriptan) 
Congenital constriction bands or amniotic bands  
C 
Selective serotonin agonists, also called triptans, are used to 
treat migraines.  Cohort studies and a manufacturer 
maintained pregnancy registry explore the teratogenicity of 
these medications, sumatriptan (N02CC01) in particular.  
First trimester exposure to sumatriptan does not significantly 
increase the rate of all CAs combined [125–130].  Eletriptan 
(N02CC06) was found to significantly increase the rate of all 
CAs combined but this was based on 14 exposures and may 
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have been a chance finding [131].  None of the other triptans 
[128,130,132], or the triptans as a group appear to increase 
the rate of all CAs combined [128,133,134]. 
 
A teratogenicity leading to signal CA described in literature 
B teratogenicity leading to other CA described in literature 
C no evidence of teratogenicity  
£ published evidence minimal 
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Figure 1 Signal evaluation flow diagram 
 
Discussion 
We have found 13 CA-medication exposure signals which require further 
confirmation.  There was evidence in the literature, albeit conflicting at times, to 
support 6 of the 13 signals [59–62,66,68,79,81,83–90,93,94,99,100,106–110].  
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These 6 signals have been strengthened and should be prioritised for further 
evaluation.  Four of these signals were related to sex hormones  (gastroschisis and 
the contraceptive levonorgestrel/ethinylestradiol; complete absence of a limb and 
pregnen (4) derivatives; hypospadias and pregnadien derivatives; hypospadias and 
synthetic ovulation stimulants). We also had as yet unvalidated data that some other 
anomalies might be associated with these medications.  Sex hormone-based 
medications accounted for 24.8% of the medication exposures in the database [Ref. 
attached article].  The other two of these signals were congenital heart defects and 
pulmonary valve stenosis associated with nucleoside/nucleotide reverse 
transcriptase inhibitors, antivirals used for HIV and chronic hepatitis.  For all of these 
signals, the possibility of confounding by indication, or by co-exposures, should be 
considered.  The progestogens are used to ‘support’ pregnancies at risk of early 
loss.  It may be that this leads to increasing survival of CA affected foetuses [135].  
Sub-fertile women have been found to have a higher risk of having a child with a CA 
regardless of whether or not they receive infertility treatment [105,136–138], and this 
or other co-exposures may confound the interpretation of medication use related to 
sub-fertility or infertility [138].  Those receiving antiviral treatment for HIV or Hepatitis 
infection, may have other exposures leading to an increased risk of CAs [139].  
However, the case-malformed control approach used in this study will have negated 
this issue to some extent as the comparison group also have CA. 
The only evidence that the antipropulsive antidiarrheals may be teratogenic was a 
single report of an association with hypospadias [50], rather than syndactyly as in 
our results. These two anomalies are usually considered aetiologically unrelated.   
The remaining six statistical signals did not have supporting evidence in the literature 
and should be confirmed in an independent dataset.  For selective serotonin 
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agonists a number of previous studies have found no association with CA [125–134] 
but these were too small to find an anomaly as rare as congenital constriction bands.  
Hydrazinophthalazine derivatives, anti-hypertensives which act on arteriolar smooth 
muscle, have one small previous negative study [51].  Other types of 
antihypertensives, such as ace inhibitors, have been associated with an increased 
risk of CA [140] but the underlying maternal hypertension also appears to play a role 
in the development of CA [141] . While there are concerns about assisted 
reproduction in general in relation to CA risk [142], and two of our other signals 
discussed above are medications used in assisted reproduction, there is only 
minimal case report evidence [111–114] relating to gonadotropin releasing hormone 
analogues, and none of these case reports relate to laterality anomalies.  Previous 
studies of the propulsives [40–47] have been negative regarding teratogenicity and 
there is no evidence to support our finding.  The ordinary salts and bulk-forming 
laxatives are generally assumed to be safe, have low bioavailablity, do not interefere 
with normal physiologic salt balance and therefore not specifically studied. 
The signal detection methodology used in EUROmediCAT was based on a 50% 
FDR.  This means that half of the associations found are expected to be chance 
associations i.e. not causal.  Due to this uncertainty, and the difficulties of 
interpretation discussed above, medication decisions should not be made based on 
the CA-medication exposure signals identified but further research should be 
conducted. 
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Strengths and Limitations  
A strength of this study is the use of the EUROmediCAT central database.  
EUROmediCAT’s international population based database contains detailed coding 
of all CAs [28] and includes TOPFA cases which constitute a large proportion of 
some CA [143].  The diagnosis of CAs is standardised across the registries involved 
and will have ensured consistency in the diagnosis [26].  There will also be much 
less under-reporting and bias than in spontaneous reporting pharmacovigilance 
systems as all major CAs are recorded in EUROCAT, not just those which clinicians 
consider to be important enough or potentially linked to a medication exposure.  
While the EUROmediCAT database contains detailed information on medications 
taken during the first trimester of pregnancy there is known under ascertainment of 
some medications [29,144] but while this may reduce the sensitivity of the system to 
detect certain teratogenic medications, it should not lead to bias due to the use of 
malformed controls.  
It was only possible to validate the data relating to the exposed cases.  This means 
that while the number of exposed cases may have decreased, due to errors found in 
data coding, the number of exposed controls will not have changed.  As a result the 
data validation process could only decrease the ORs.  We found evidence that other 
anomalies were also associated with the signal medications, but at lower levels of 
statistical significance which did not surpass the FDR threshold, and did not validate 
these data.  However, data validation for the main findings is a strength of this study. 
The signal detection process used did not take prior literature into account during the 
statistical analysis [145] but instead brought this in at the signal evaluation stage.  In 
the EUROmediCAT analyses of antiepileptics, antidiabetics, antidepressants and 
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antiasthmatics [20–23], we first searched the literature before evaluating existing 
signals and detecting new signals. The signal detection process we report in this 
paper is intended to be used in addition to the drug class by drug class approach. It 
can be used to identify the most highly significant associations in the database for 
drug classes not otherwise undergoing analysis.  We recognise that there may be 
many other associations in the data that did not meet the FDR threshold but which 
are nevertheless of potential interest. Indeed, this is as shown by our evaluation of 
the 16 signals arising from the original signal detection analysis which included a 
number of associations reported previously in the literature. 
While the literature search was extensive it is possible that relevant articles may 
have been missed, particularly negative evidence for a medication exposure when 
analysed as one of many aetiological factors in a case-control study.  We were 
assessing whether previous literature existed but did not conduct a meta-analysis of 
the evidence to date, and this may lead to highlighting positive over negative 
evidence, although all evidence found is presented.  It was necessary to search for 
each of the individual medications, rather than the broader medication group as the 
4th ATC level, chemical subgroup, was not always used in the literature or 
databases and returned little or no information for some of the signals.  Without prior 
hypotheses about the mechanism of action, it can also be difficult to decide how 
broadly to look for related literature – for example there is a large literature on sex 
hormones as a class, but much less related to specific sex hormones.  While positive 
evidence in the literature regarding risk of all CAs combined could be considered 
supportive, negative evidence is more difficult to interpret, since few medications 
increase the rate of all CAs combined, instead tending to increase the rate of specific 
CAs [146]. 
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As far as possible changes, over time, in the ATC codes used for particular 
medications were taken into account in both the signal detection analysis and the 
signal evaluation.  It is possible however that some changes were missed, potentially 
leading to signals being missed as the exposed cases would be split across more 
than one ATC code in the dataset. 
Although all the cases were confirmed as first trimester exposures it is not known if 
these exposures actually occurred during the critical period for CA development [8].  
Similarly there was no information available in terms of the doses of medications 
taken for the majority of cases.  If it was possible to identify a dose response 
relationship or show exposure during the critical period for development of the 
specific CAs this would provide support for a causal relationship [146].  Our protocol 
did not include assessment of biological plausibility or possible teratogenic 
mechanisms [147].  Although grouping of CA or of medications by potential 
teratogenic mechanism has been advocated [3], we found this to be of limited use 
since the same CA are often related to a number of potential mechanisms, and the 
current imperfect knowledge of mechanisms is one of the drivers of signal detection 
in postmarketing surveillance. 
Conclusion 
A statistical signal detection analysis was conducted using the EUROmediCAT 
central database.  Six signals had some prior supporting evidence and these should 
be prioritised for further investigation before being evaluated in relation to clinical 
decision making. A further seven CA-medication exposure signals were found which 
had no prior supporting evidence and these need to be confirmed in independent 
datasets.   
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Supplementary Table 1: EUROmediCAT signal detection dataset 
EUROCAT Registry 
Birth years 
enrolled 
Exposed 
Foetuses 
with 
Congenital 
anomalies 
(n) 
 Foetuses with 
Congenital anomalies 
following data cleaning 
by timing of exposurea 
(n) 
Data loss 
by data 
cleaning 
(%) 
Total eligible 
ATC-coded 
exposures (n) 
Average 
number of 
ATC-coded 
medication 
exposures per 
pregnancy 
Belgium, Antwerp 1997-2011 358 354 1 529 1.49 
Croatia, Zagreb 1995-2010 184 180 2 228 1.27 
Denmark, Odense 1995-2011 234 234 0 357 1.53 
France, Paris 2001-2011 659 659 0 968 1.47 
Germany, Mainz 2005-2011 142 139 2 158 1.14 
Ireland, Cork & Kerry 1996-2009 259 258 0 355 1.38 
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Italy, Emilia 
Romagnab, c 
1995-2011 2,322 2,322 0 3,826 1.65 
Italy, Tuscany 1995-2011 1,082 1,043 4 1,418 1.36 
Malta 1996-2011 298 297 0 445 1.50 
Netherlands, North 
Netherlands 
1995-2011 2,374 1,844 22 3,036 1.65 
Norway 2005-2010 3,052 3,052 0 5,537 1.81 
Poland (excl. 
Wielkopolska) 
1999-2010 11,997 1,958 84 2,450 1.25 
Poland, 
Wielkopolska 
1999-2010 2,713 409 85 552 1.35 
Switzerland, Vaud 1997-2011 298 294 1 435 1.48 
UK, Wales 1998-2011 1,907 1,907 0 2,807 1.47 
Total 1995-2011 27,879 14,950 46 23,101 1.55 
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a Exclusion of CA registrations with only medication exposures of unknown timing  
b During the period 1995 to 2004 Emilia Romagna database had space for only 5 medications to be recorded. 
c Terminations of pregnancy for fetal anomalies were excluded from the Emilia Romagna registry as information on medications is 
only available for live and still births 
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Supplementary document 1: Literature review methodology 
 
Databases 
REPROTOX (http://reprotox.org) 
This database is extensive and covers a wide range of exposures including medications, 
vaccines, illicit substances and chemicals.  Information is provided with an initial summary 
followed by a review of the literature.  This review covers evidence of teratogenicity in 
animals and humans, potential effects of the chemical on the pregnancy (for e.g. 
delaying/stimulating delivery) or neonate (for e.g. respiratory depression after delivery or 
neurological side effects in later life) and information relating to breast feeding.  This review 
is well referenced and frequently updated (usually within the previous month or two).   
Caution should be used when a drug group, rather than a specific drug, is being reviewed.  
As per the issues highlighted below, in terms of the difficulties in finding appropriate 
information relating to the 4th ATC level, a review of a drug group can miss important 
associations in the literature.  For example (at the time of conducting the literature review for 
this article) the summary relating to Selective Serotonin Reuptake Inhibitors (SSRIs) did not 
include a paper from the New England Medical Journal - ‘Use of Selective Serotonin-
Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects’.  This article was included in 
the REPROTOX reviews relating to specific SSRIs but not in the review relating to the drug 
group.  This highlights the methodological difficulties in summarising the evidence at a drug 
group (3rd or 4th ATC level) compared to an individual drug level (5th ATC level).   
 
TOXBASE (http://www.toxbase.org) 
This database is produced by the UK Teratology Information Service.  While it covers 
chemical exposure, self-poisoning (deliberate or accidental) and snake bites etc. it also has 
a section specifically for exposures which occur during pregnancy.  This section covers a 
wide range of drug or chemical exposures as well as a number of maternal health 
conditions.  Unlike REPROTOX this database is restricted to drugs prescribed in the UK. 
The information provided starts off with the summary information which is available on the 
UKTIS website.  The document then details: preclinical (animal) data, human data 
(congenital malformations, neonatal effects, overdose in pregnancy, NICE guideline 
recommendations and paternal exposure) and the outcome of any exposure cases reported 
to NTIS (prospectively and retrospectively).  References to the literature are provided in this 
document but these documents may not have been updated for a while.    
 
DART (Developmental and Reproductive Toxicology) 
http://toxnet.nlm.nih.gov/newtoxnet/dart.htm 
DART (one of the TOXNET databases) provides more than 200,000 journals references 
covering teratology and other aspects of developmental and reproductive toxicology.  It has 
references from the early 1900s to the present. New references are added weekly.  The vast 
majority of references returned are relevant to teratogenicity.   
 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) 
PubMed comprises more than 25 million citations for biomedical literature from MEDLINE, 
life science journals, and online books. PubMed citations and abstracts include the fields of 
biomedicine and health, covering portions of the life sciences, behavioural sciences, 
chemical sciences, and bioengineering. As this database is not limited to references relating 
to teratology it is necessary to include additional search terms to identify relevant literature.  
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ATC classification 
There are 5 levels in the ATC classification.  The complete classification of metformin below 
illustrates the structure of the code: 
 A Alimentary tract and metabolism 
 (1st level, anatomical main group) 
 
 A10 Drugs used in diabetes 
 (2nd level, therapeutic subgroup) 
 
 A10B Blood glucose lowering drugs, excl. insulins 
 (3rd level, pharmacological subgroup) 
 
 A10BA Biguanides 
 (4th level, chemical subgroup) 
 
 A10BA02 metformin 
 (5th level, chemical substance) [1].   
 
There is often nothing available in the literature specifically relating to the teratogenicity of 
drugs at a 4th level (e.g. biguanides).  However when searching at the 3rd ATC level (e.g. 
blood glucose lowering drugs excluding insulins) it was almost impossible to pull out 
information relating specifically to the 4th group level.  You also miss a lot of relevant 
literature doing this and importantly the WHO states that:  ‘Substances classified in the same 
ATC 4th level (4ths) cannot be considered pharmacotherapeutically equivalent since their 
modes of action, therapeutic effects, drug interactions and adverse drug reaction profiles 
may differ’ [1]. In an attempt to identify as much relevant literature as possible relating to a 
4th level signal it was therefore necessary to also search for each drug at the 5th level which 
contributed to the 4th level group. 
 
Search process 
1. TOXBASE and REPROTOX  
Used to get a summary re: teratogenicity and to identify the main articles. Searched using 
the chemical substance and subgroup names (5th and 4th ATC levels), as shown in table 1 
below.   
 
2. DART and PubMed 
Used to identify any older, more recent or obscure articles which were not included in the 
TOXBASE or REPROTOX summaries. Searched using terms to represent the chemical 
substance and subgroup names (5th and 4th ATC levels), as shown in table 1 below. 
Additional search terms were included in order to restrict the search results to literature 
relevant to potential drug teratogenicity i.e. ‘terat*’, ‘congen*’, ‘malf*’ and ‘’anom*’.   
 
3. Reference list of identified articles 
Used to identify any older or obscure articles which were not previously identified.  
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Table 1 Signal search terms 
Signal 
drug/group 
4th ATC level DART and 
PubMed 4th ATC 
level search 
terms  
5th ATC level  DART and 
PubMed 5th 
ATC level 
search terms 
A02AD01 
Ordinary salt 
combinations 
Combinations 
and 
complexes of 
aluminium, 
calcium and 
magnesium 
compounds 
 (aluminium 
AND 
compound*) 
 (calcium AND 
compound*)  
 (magnesium 
AND 
compound*) 
 Ordinary salt 
combinations 
 Magaldrate 
 Almagate  
 Hydrotalcite 
 Almasilate 
 (ordinary 
AND salt) 
 magaldrate 
 almagate 
 hydrotalcite 
 almasilate 
A03FA 
Propulsives  
Propulsives  propulsive*  Metocloprami
de  
 Cisapride  
 Domperidone  
 Bromopride  
 Alizapride  
 Clebopride  
 Itopride 
 metocloprami
de  
 cisapride  
 domperidone  
 bromopride  
 alizapride  
 clebopride  
 itopride 
A06AC Bulk-
forming 
laxatives 
Bulk-forming 
laxatives 
 (bulk AND 
laxative*) 
 Ispaghula 
(psylla seeds) 
 Ethulose 
 Sterculia 
 ispaghula  
 psylla  
 ethulose 
 sterculia 
58 
 
 Linseed 
 Methylcellulos
e 
 Triticum 
(wheat fibre) 
 Polycarbophil 
calcium 
 Ispaghula 
combinations 
 Sterculia 
combinations 
 Linseed 
combinations 
 linseed 
 methylcellulos
e 
 triticum  
 (wheat AND 
fibre) 
 polycarbophil  
 
A07DA 
Antipropulsive
s  
Antipropulsive
s 
 antipropulsiv
e* 
 Diphenoxylat
e 
 Opium 
 Loperamide 
 Difenoxin 
 Loperamide 
oxide 
 Morphine 
combinations  
 Loperamide 
combinations 
 diphenoxylate 
 opium 
 loperamide 
 difenoxin 
 (morphine 
AND 
combination*) 
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C02DB 
Hydrazinophth
alazine 
derivatives 
Hydrazinophth
alazine 
derivatives 
 hydrazinopht
halazine 
 Dihydralazine  
 Hydralazine 
 Endralazine  
 Cadralazine 
 dihydralazine  
 hydralazine 
 endralazine  
 cadralazine 
G03AB03/G03
AA07 
Levonorgestrel 
and 
ethinylestradio
l  
 Progestog
ens and 
estrogens, 
sequential 
preparation
s 
 Progestog
ens and 
estrogens, 
fixed 
combinatio
ns 
 progestogen* 
 estrogen* 
 oestrogen* 
 Quingestanol 
and 
ethinylestradi
ol  
 Lynestrenol 
and 
ethinylestradi
ol  
 Megestrol 
and 
ethinylestradi
ol 
 Norethisteron
e and 
ethinylestradi
ol 
 Norgestrel 
and 
ethinylestradi
ol 
 quingestanol  
 lynestrenol  
 Megestrol  
 norethisteron
e  
 norgestrel  
 levonorgestrel  
 medroxyprog
esterone  
 desogestrel  
 gestodene  
 norgestimate  
 drospirenone  
 norelgestromi
n  
 nomegestrol  
 chlormadinon
e  
 dienogest  
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 Levonorgestr
el and 
ethinylestradi
ol 
 Medroxyprog
esterone and 
ethinylestradi
ol 
 Desogestrel 
and 
ethinylestradi
ol 
 Gestodene 
and 
ethinylestradi
ol 
 Norgestimate 
and 
ethinylestradi
ol 
 Drospirenone 
and 
ethinylestradi
ol 
 ethinylestradi
ol  
 estradiol 
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 Norelgestromi
n and 
ethinylestradi
ol 
 Nomegestrol 
and estradiol 
 Chlormadinon
e and 
ethinylestradi
ol 
 Dienogest 
and 
ethinylestradi
ol 
G03DA 
Pregnen (4) 
derivatives  
Pregnen (4) 
derivatives 
 pregnen  Gestonorone 
 Medroxyprog
esterone 
 Hydroxyproge
sterone  
 Progesterone 
 gestonorone 
 medroxyprog
esterone 
 hydroxyproge
sterone  
 progesterone 
G03DB 
Pregnadien 
derivatives  
Pregnadien 
derivatives 
 pregnadien  Dydrogestero
ne 
 Megestrol 
 Medrogeston
e 
 dydrogestero
ne 
 megestrol 
 medrogeston
e 
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 Nomegestrol 
 Demegestone 
 Chlormadinon
e 
 Promegeston
e  
 Dienogest 
 nomegestrol 
 demegestone 
 chlormadinon
e 
 promegeston
e  
 dienogest 
G03GB 
Synthetic 
ovulation 
stimulants  
Synthetic 
ovulation 
stimulants 
 (synthetic 
AND ovulat*) 
 (ovulat* AND 
stimul*) 
 Cyclofemil 
 Clomifene 
 Epimestrol 
 cyclofemil 
 clomifene 
 epimestrol 
L02AE 
Gonadotropin 
releasing 
hormone 
analogues 
(GnRHa) 
Gonadotropin 
releasing 
hormone 
analogues 
(GnRHa) 
 gonadotropin  
 GnRHa  
 gnrha 
 GnRH 
 gnrh 
 Buserelin 
 Leuprorelin 
 Gosorelin 
 Triptorelin  
 Histrelin 
 buserelin 
 leuprorelin 
 gosorelin 
 triptorelin  
 histrelin 
J05AF 
Nucleoside 
and nucleotide 
reverse 
transcriptase 
inhibitors 
(Ns/NtRTIs)  
Nucleoside 
and nucleotide 
reverse 
transcriptase 
inhibitors 
(Ns/NtRTIs) 
 nucleoside 
 nucleotide 
 (nucleoside 
AND 
nucleotide) 
 Ns/NtRTI* 
 Zidovudine 
 Didanosine 
 Zalcitabine 
 Stavudine 
 Lamivudine 
 Abacavir 
 zidovudine 
 didanosine 
 zalcitabine 
 stavudine 
 lamivudine 
 abacavir 
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J05AF30 
Combinations 
of nucleoside 
and nucleotide 
reverse 
transcriptase 
inhibitors  
 ns/ntrti*  Tenofovir 
disoproxil 
 Adefovir 
dipivoxil 
 Emtricitabine 
 Entecavir 
 Telbivudine 
 Clevudine 
 tenofovir  
 adefovir 
 emtricitabine 
 entecavir 
 telbivudine 
 clevudine 
N02CC 
Selective 
serotonin 
(5HT1) 
agonists  
Selective 
serotonin 
(5HT1) 
agonists 
 (selective 
AND 
serotonin) 
 (serotonin 
AND 
agonist*) 
 triptan* 
 5HT1 
 5ht1 
 Sumatriptan 
 Naratriptan 
 Rizatriptan 
 Almotriptan 
 Eletriptan 
 Frovatriptan 
 sumatriptan 
 naratriptan 
 rizatriptan 
 almotriptan 
 eletriptan 
 frovatriptan 
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